" class="no-js "lang="en-US"> Anthos Therapeutics Appoints David McIntyre as Chief Financial Officer - Medtech Alert
Monday, April 15, 2024

Anthos Therapeutics Appoints David McIntyre as Chief Financial Officer

Anthos Therapeutics, a late-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced the appointment of David McIntyre as Chief Financial Officer. Mr. McIntyre will assume responsibility for the company’s finance and investor relation functions, and joins Anthos as its lead product candidate, abelacimab, expects to become the first ‘hemostasis-sparring’ Factor XI anticoagulant to enter Phase 3 clinical studies in the United States.

“With the recent completion of enrollment in our Phase 2b atrial fibrillation (AF) study and the goal of initiating three Phase 3 clinical studies for abelacimab within the next twelve months, David strengthens our leadership team as we aim to become the first Factor XI anticoagulant seeking approval for the treatment and prevention of thromboembolism in various cardiovascular conditions,” said John Glasspool, CEO, Anthos Therapeutics. “David brings a successful track record in both public and private healthcare companies and his financial, transactional, and legal experience adds significant value to our organization going forward.”

Mr. McIntyre added, “Factor XI therapies are becoming increasingly recognized as a paradigm shift in anticoagulation as they are able to pharmacologically uncouple thrombosis from the bleeding and tolerability challenges commonly encountered with conventional anticoagulation therapies. I am excited to be joining a team made up of outstandingly talented individuals and investors working to bring abelacimab to the market so as to meet this serious medical need in anticoagulation.”

Mr. McIntyre is an experienced healthcare executive having spent more than twenty years in various finance roles, including C-suite level roles across multinational and growth stage entities such as Tessa Therapeutics, Inc., AVITA Therapeutics, Inc. , HeartWare® International, Inc., and Braeburn, Inc. Mr. McIntyre’s experience also includes nearly ten years as a Partner at Apple Tree Partners, a multi-billion-dollar life science venture capital and growth equity fund, giving him a deep knowledge of the US biotech and medical device markets.

Mr. McIntyre holds a Bachelor of Economics (Accounting) from the University of Sydney (Australia), a Bachelor of Laws from the University of Technology, Sydney (Australia) and a Master of Business Administration from Duke University (Fuqua Scholar). He is also a Certified Practicing Accountant and is admitted as a legal practitioner of the Supreme Court of the State of New South Wales (Australia) and of the High Court of Australia.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more